Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy

Stegemann, Sven; Gosch, M.; Breitkreutz, Jörg

doi:10.1016/j.ijpharm.2012.04.022

Cited by 190 publications

(134 citation statements)

References 91 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Orodispersible tablet (ODT) is good for such subpopulations, in general for paediatric and geriatric patients 1 or patients with swallowing dysfunction or dysphagia 2 . ODTs disintegrate in the oral cavity within seconds and are washed out with saliva without the need of liquid 3 .…”

Section: Introductionmentioning

confidence: 99%

Formulation and development of orodispersible sustained release tablet of domperidone

Patil

Tiwari

Repka

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Abstract:Commercially available domperidone orodispersible tablets (ODT) are intended for immediate release of the drug but none of them have been formulated for sustained action. The aim of the present research work was to develop and evaluate orodispersible sustained release tablet (ODT-SR) of domperidone, which has the convenience of ODT and benefits of controlled release product combined in one. The technology comprised of developing sustained release microspheres (MS) of domperidone, followed by direct compression of MS along with suitable excipients to yield ODT-SR which rapidly disperses within 30 seconds and yet the dispersed MS maintain their integrity to have a sustained drug release. The particle size of the MS was optimized to be less than 200 μm to avoid the grittiness in the mouth. The DSC thermograms of MS showed the absence of drug-polymer interaction within the microparticles, while SEM confirmed their spherical shape and porous nature. Angle of repose, compressibility and Hausner's ratio of the blend for compression showed good flowability and high percent compressibility. The optimised ODT-SR showed disintegration time of 21 seconds and matrix controlled drug release for 9 h. Invivo pharmacokinetic studies in Wistar rats showed that the ODT-SR had a prolonged MRT of 11.16 h as compared 3.86 h of conventional tablet. The developed technology is easily scalable and holds potential for commercial exploitation.

show abstract

Section: Introductionmentioning

confidence: 99%

Formulation and development of orodispersible sustained release tablet of domperidone

Patil

Tiwari

Repka

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

show abstract

“…Kompensatorische Mechanismen können im Alter jedoch eine manifeste Presbydysphagie verhindern oder herauszögern [55]. Diese Kompensationsleistung kann allerdings durch Medikamente empfindlich gestört werden, vor allem bei der im Alter häufig vorliegenden "multiplen" Medikation [19] rate (die durch ihre sedierende Wirkung geradezu "klassisch" die Schluckfunktion negativ beeinflussen können) mit 14,7 % die häufigste Medikamentengruppe [47].…”

Section: » Antikonvulsive Medikamente Können Ein Bestehendes Schluckdunclassified

“…Viele zentral wirkende Medikamente bewirken eine Xerostomie, die durch anticholinerge Effekte oder eine Modulation der Signalwege, welche die Speicheldrüsen beeinflussen, zu erklä-ren ist [55]. Unter den Antidepressiva ist der bekannteste Vertreter die Gruppe der trizyklischen Antidepressiva (z.…”

Section: Xerostomieunclassified

See 1 more Smart Citation

Medikamenteninduzierte Dysphagien

Schwemmle

Jungheim

Miller

et al. 2015

HNO

View full text Add to dashboard Cite

“…Despite this growing demand, pediatric drug formulation science is still at an early stage, as it is complex, multiparametric, and resource and time intensive. As discussed previously, tablets and capsules cannot be swallowed by the very young, while liquid formulations may present multiple portability, stability, and dose accuracy problems (30,31).…”

Section: Innovative Pediatric Formulations and Administration Devicesmentioning

confidence: 99%

A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms

Zajicek

Fossler

Barrett

et al. 2013

AAPS J

View full text Add to dashboard Cite

Abstract. Despite the fact that a significant percentage of the population is unable to swallow tablets and capsules, these dosage forms continue to be the default standard. These oral formulations fail many patients, especially children, because of large tablet or capsule size, poor palatability, and lack of correct dosage strength. The clinical result is often lack of adherence and therapeutic failure. The American Association of Pharmaceutical Scientists formed a Pediatric Formulations Task Force, consisting of members with various areas of expertise including pediatrics, formulation development, clinical pharmacology, and regulatory science, in order to identify pediatric, manufacturing, and regulatory issues and areas of needed research and regulatory guidance. Dosage form and palatability standards for all pediatric ages, relative bioavailability requirements, and small batch manufacturing capabilities and creation of a viable economic model were identified as particular needs. This assessment is considered an important first step for a task force seeking creative approaches to providing more appropriate oral formulations for children.

show abstract

Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy

Cited by 190 publications

References 91 publications

Formulation and development of orodispersible sustained release tablet of domperidone

Formulation and development of orodispersible sustained release tablet of domperidone

Medikamenteninduzierte Dysphagien

A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms

Contact Info

Product

Resources

About